Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hair loss drug ritlecitinib tested for Long-Term safety in teens

NCT ID NCT07029828

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the long-term safety and effects of the drug ritlecitinib for severe alopecia areata, a condition causing significant hair loss. It involves 140 teens who previously completed Pfizer studies on this drug. Participants take a daily capsule for up to 3 years, with regular clinic visits and monthly phone calls to monitor results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ritlecitinib (oral capsule)
What this could lead to
If it works, this could confirm ritlecitinib as a long-term treatment option for severe hair loss due to alopecia areata.
What could go wrong
This is an extension study, so it builds on earlier results but still focuses on safety and may not show strong hair regrowth. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 14 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants with alopecia areata (AA) (including alopecia totalis \[AT\] and alopecia universalis \[AU\]) who completed the studies B7981027 or B7981031. 2. For participants originating from Study B7981031: At least 50% scalp hair loss due to AA (ie, a SALT score of ≥50) at both the Screening and Baseline visits. Exclusion Criteria: 1. Exclusion criteria for participants originating from Study B7981027 with ≤ 30 Days between last dose in Study B7981027 and first visit of Study B7981028 1. During Study B7981027 or in the period between the last dose of study intervention in Study B7981027 and the first dose of study intervention of Study B7981028, presence of safety events that would require permanent discontinuation based on the B7981028 protocol. 2. Study participants discontinued from Study B7981027 due to issues other than safety-related events and considered by the investigator for enrolment in Study B7981028 must have resolution of the issue(s) resulting in discontinuation from the parent study prior to enrolment in Study B7981028. 2. Exclusion criteria for participants originating from Study B7981031 or from Study B7981027 with \>30 Days between last dose in Study B7981027 and first visit of Study B7981028 1. During Study B7981031 or Study B7981027 or in the period between the last dose of study intervention in Study B7981031 or Study B7981027 and the first dose of study intervention of Study B7981028, presence of safety events that would require permanent discontinuation based on the B7981028 protocol. 2. Any present malignancies or history of malignancies or lymphoproliferative disorders. 3. Evidence of untreated or inadequately treated active or latent Mycobacterium tuberculosis (TB) infection, history (one or more episodes) of severe or serious cytomegalovirus (CMV), herpes zoster (shingles) or disseminated herpes simplex, infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe alopecia areata are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe alopecia areata

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    41 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 3A Research

    RECRUITING

    El Paso, Texas, 79902, United States

  • CHU de Dijon Bourgogne

    NOT_YET_RECRUITING

    Dijon, 21079, France

  • California Dermatology & Clinical Research Institute

    RECRUITING

    Encinitas, California, 92024, United States

  • Centre Hospitalier Universitaire de Nice

    NOT_YET_RECRUITING

    Nice, 06202, France

  • Centre Hospitalier Universitaire de Toulouse - Hôpital Larrey

    NOT_YET_RECRUITING

    Toulouse, 31400, France

  • Centrum Medyczne Angelius Provita

    NOT_YET_RECRUITING

    Katowice, Silesian Voivodeship, 40-611, Poland

  • Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska

    NOT_YET_RECRUITING

    Wroclaw, Lower Silesian Voivodeship, 50-566, Poland

  • Complete Behavior Health (Dr. Brittany Marshall, Licensed Psychologist)

    RECRUITING

    Papillion, Nebraska, 68046, United States

  • D&H Tamarac Research Center

    NOT_YET_RECRUITING

    Tamarac, Florida, 33321, United States

  • DERMEDIC Iwona Zdybska

    NOT_YET_RECRUITING

    Lublin, Lublin Voivodeship, 20-607, Poland

  • Dawes Fretzin Clinical Research Group, LLC

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak

    NOT_YET_RECRUITING

    Lodz, Łódź Voivodeship, 90-436, Poland

  • Ear, Nose & Throat Consultants, LLC

    RECRUITING

    Omaha, Nebraska, 68144, United States

  • Equity Medical, LLC

    NOT_YET_RECRUITING

    The Bronx, New York, 10455, United States

  • GHICL - Service d'investigation - Recherche clinique

    NOT_YET_RECRUITING

    Lille, 59000, France

  • Hamamatsu University Hospital

    RECRUITING

    Hamamatsu, Shizuoka, 431-3192, Japan

  • Hospices Civils de Lyon - Hopital Femme Mere Enfant

    NOT_YET_RECRUITING

    Bron, 69500, France

  • Huashan Hospital, Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200040, China

  • Hôpital Saint Vincent de Paul

    NOT_YET_RECRUITING

    Lille, 59020, France

  • Hôpitaux Drôme Nord

    NOT_YET_RECRUITING

    Romans-sur-Isère, 26100, France

  • Kindred Hair and Skin Center

    NOT_YET_RECRUITING

    Marriottsville, Maryland, 21104, United States

  • Klinika Ambroziak Dermatologia

    NOT_YET_RECRUITING

    Warsaw, Masovian Voivodeship, 02-953, Poland

  • Klinika Osipowicz & Turkowski

    NOT_YET_RECRUITING

    Warsaw, Masovian Voivodeship, 00-716, Poland

  • Kyorin University Hospital

    NOT_YET_RECRUITING

    Mitaka, Tokyo, 181-8611, Japan

  • Medical University of South Carolina Department of Dermatology and Dermatologic Surgery

    NOT_YET_RECRUITING

    Charleston, South Carolina, 29425, United States

  • Michigan Dermatology Institute

    NOT_YET_RECRUITING

    Waterford, Michigan, 48328, United States

  • Northwest Dermatology Institute

    RECRUITING

    Portland, Oregon, 97210, United States

  • Osaka Metropolitan University Hospital

    RECRUITING

    Osaka, 545-8586, Japan

  • Państwowy Instytut Medyczny MSWiA

    NOT_YET_RECRUITING

    Warsaw, Masovian Voivodeship, 02-507, Poland

  • Pediatric Skin Research

    RECRUITING

    Miami, Florida, 33156, United States

  • Penn State Health Milton S. Hershey Medical Center

    NOT_YET_RECRUITING

    Hershey, Pennsylvania, 17033, United States

  • Prof. MUDr. Petr Arenberger, DrSc., MBA

    NOT_YET_RECRUITING

    Prague, 11000, Czechia

  • Provita Poliklinika

    NOT_YET_RECRUITING

    Warsaw, Masovian Voivodeship, 02-647, Poland

  • Regents of the University of New Mexico

    RECRUITING

    Albuquerque, New Mexico, 87131, United States

  • Royalderm Agnieszka Nawrocka

    NOT_YET_RECRUITING

    Warsaw, Masovian Voivodeship, 02-962, Poland

  • Skin Specialists, PC dba Schlessinger MD

    RECRUITING

    Omaha, Nebraska, 68144, United States

  • Texas Dermatology and Laser Specialists

    RECRUITING

    San Antonio, Texas, 78218, United States

  • Tohoku University Hospital

    NOT_YET_RECRUITING

    Sendai, Miyagi, 980-8574, Japan

  • University of New Mexico Health Sciences Center

    RECRUITING

    Albuquerque, New Mexico, 87102, United States

  • University of New Mexico-IDS Pharmacy

    RECRUITING

    Albuquerque, New Mexico, 87106, United States

  • Uniwersytecki Szpital kliniczny im. F. Chopina w Rzeszowie

    NOT_YET_RECRUITING

    Rzeszów, 35-055, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.